IRCCS Centro di Riferimento Oncologico della Basilicata
Quick facts
Phase 3 pipeline
- Lenalidomide, dexamethasone · Oncology
Lenalidomide enhances immune cell proliferation and anti-tumor activity while dexamethasone provides anti-inflammatory and immunomodulatory effects to treat multiple myeloma.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- IRCCS Centro di Riferimento Oncologico della Basilicata portfolio CI brief
- IRCCS Centro di Riferimento Oncologico della Basilicata pipeline updates RSS
Frequently asked questions about IRCCS Centro di Riferimento Oncologico della Basilicata
What is IRCCS Centro di Riferimento Oncologico della Basilicata's pipeline?
IRCCS Centro di Riferimento Oncologico della Basilicata has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Lenalidomide, dexamethasone.
Related
- Sector hub: All tracked pharma companies